UNSPSC 51111845: Dromostanolone or drostanolone

This classification denotes a therapeutic androgen with the molecular formula C20H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7DR7H00HDT, chemically known as (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one but generally known as dromostanolone, which bears US NIH Compound Identifier 6011. SMILES:CC1CC2(C(CCC3C2CCC4(C3CCC4O)C)CC1=O)C. Dromostanolone or drostanolone bears US NLM identifiers UMLS ID C0058753 and NCI Concept Code C1076.

UNSPSC 51111845 Dromostanolone or drostanolone is a Commodity code covering anabolic steroid pharmaceuticals supplied through state and local cooperative purchasing agreements. State and local governments procure these controlled pharmaceutical products through multistate cooperative contracts that establish pricing, distribution terms, and compliance frameworks with authorized wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issues the primary recent solicitation under this code and represents the issuing-body pattern — multistate cooperative purchasing organizations that aggregate demand across participating state and local government facilities, hospitals, and related public healthcare entities. Vendors responding to these procurements must hold current Good Manufacturing Practices (cGMP) certification, comply with Drug Supply Chain Security Act (DSCSA) requirements, maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and carry comprehensive insurance including $5 million in commercial general liability, $2 million in network security and privacy liability, and $2 million in professional liability.

MMCAP's most recent solicitation, S1070000015802 Generic Multi Source Pharmaceuticals and OTC Products, is an RFP issued January 20, 2026 with a response deadline of March 26, 2026 and contract effectiveness date of July 1, 2026. The procurement spans Minnesota and Oregon, with awards expected to multiple vendors based on therapeutic considerations and product availability. Evaluation weighting emphasizes price competitiveness (75 percent) and fixed pricing for the contract term (10 percent), with additional weight given to EDI capability (5 percent), administrative compliance (5 percent), and agreement to a 3 percent administrative fee (5 percent). Contract terms run two years for new responders with optional extensions at MMCAP's discretion; incumbent responders' amendments align with existing agreement expirations through June 30, 2028. Vendors must submit pricing and product information in CSV format through the ePro procurement system using Google Chrome, with a questions cutoff date of February 18, 2026.